If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
143
results.
Updated on
19/07/2025 [07:15:00]
Results 50 to 75 of 143
Absstract of: GB2636672A
A method and an apparatus utilizing targeted ion mobility spectrometry for the detection of the SARS-CoV-2 virus and its variants, by measuring the quantity of free polyamines including putrescine, spermidine, and spermine in a sublingual saliva sample. Other embodiments are capable of providing instant, cost effective, POC testing and test results for other viral and bacterial infections including influenza, acute and chronic respiratory conditions, certain forms of inflammation, and the detection of certain abnormal cells in human subjects.
Absstract of: ZA202401786B
Disclosed is a method for treating a subject that has previously been infected with SARS-CoV-2 and exhibiting at least one Post COVID- 19 Conditions of fatigue (PCC of fatigue) symptom. The method comprises administering to the subject a therapeutically effective amount of a composition comprising therapeutic double-stranded RNA (tdsRNA). Compositions, medicaments and delivery systems comprising tdsRNA for the treatment of PCC of fatigue are also disclosed.
Absstract of: AU2023326053A1
Described herein are methods and related compositions for determining the likelihood of neurological post-acute sequelae of COVID-19 (NP ASC) in a subject based on the levels of biomarkers in a combination of biomarkers from a biological sample from the subject. Also disclosed herein are methods for treating a subject identified as having a high likelihood of suffering from NP ASC and treating the subject by modulating the level or activity of an NPASC therapeutic target identified herein.
Absstract of: KR20220166497A
The present invention relates to a composition containing a Schisandra chinensis extract as an active ingredient for preventing or treating coronavirus infection-19 (COVID-19). The Schisandra chinensis extract according to the present invention was confirmed to suppress invasion of inflammatory cells in alveoli, to reduce expression of ACE2, which is an RBD receptor, and p-STAT3 and IL-6, which are inflammation-related factors, to suppress phosphorylation of JNK, ERK, p38, IκB, and NFκB in an inflammatory signal transduction pathway, and to increase the expression of Nrf2 and NQO-1, which are antioxidant factors, in a respiratory disease mouse induced by a receptor-binding domain (RBD), which is a protein constituting a spike of SARS-CoV-2. Accordingly, it can be usefully used in related industries.
Absstract of: WO2025127420A1
The present invention relates to engineered human antibodies having neutralizing activity against human coronavirus and use thereof. The novel human antibodies against coronavirus, of the present invention, specifically bind to SARS-CoV-1, SARS-CoV-2, or a variant thereof, exhibit neutralizing activity against SARS-CoV-1, SARS-CoV-2, or a variant thereof, and have cross-reactivity, and thus can be used for the prevention or treatment of coronavirus infection. In addition, the antibodies and fragments having immunological activities thereof can be used to rapidly detect various types of coronaviruses, and thus can be used for the immunodiagnosis of human coronaviruses, particularly SARS-CoV-2 with high infectivity, and variants thereof.
Absstract of: US2025195639A1
In various embodiments immunogenic nanoparticles are provided that are capable of raising an immune response directed against SARS-CoV-2. In certain embodiments the immunogenic nanoparticles comprise mRNA multi-epitope vaccines that can be used in combination with or independent of other covid-19 vaccines (e.g., the spike protein mRNA vaccine(s)) to invoke a strong CD8+ or CD4+ T-cell as well as neutralizing antibody producing B-cell responses. In certain embodiments this vaccine is based on the rational combination of well-conserved T- and B-cell epitopes identified COVID-19 and viral variants.
Absstract of: WO2025127075A1
The problem addressed is to provide surface-modified iron oxide nanoparticles for use in a vaccine exhibiting an infection preventive effect on SARS-CoV-2. The problem can be solved by surface-modified iron oxide nanoparticles comprising SARS-CoV-2 spike protein and iron oxide nanoparticles, where the spike protein of SARS-CoV-2 is bound to the surface of the iron oxide nanoparticles.
Absstract of: US2025195557A1
An objective of the present invention is to provide a nonpharmaceutical anti-human coronavirus composition that prevents human coronavirus infections, the onset of the infections, or aggravation of symptoms of the infections. The anti-human coronavirus composition according to the present invention includes an exopolysaccharide produced by a lactic acid bacterium in genus Lactobacillus as an active component. The lactic acid bacterium in the genus Lactobacillus may belong to a Lactobacillus delbrueckii species. The lactic acid bacterium in the genus Lactobacillus may specifically be Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 (FERM BP-10741).
Absstract of: US2025201406A1
Method for predicting severity of COVID-19 disease resulting from infection with SARS-COV-2 (severe acute respiratory syndrome coronavirus 2). The method uses a high dimensional approach to construct a comprehensive metabolic landscape of immune cells participating in the anti-viral response against SARS-CoV-2. Also encompassed within the invention are novel immune cell subsets exhibiting metabolic dysfunction that could serve as predictive biomarkers for COVID-19 severity or as targets for therapeutic interventions in COVID-19 disease.
Absstract of: WO2025127420A1
The present invention relates to engineered human antibodies having neutralizing activity against human coronavirus and use thereof. The novel human antibodies against coronavirus, of the present invention, specifically bind to SARS-CoV-1, SARS-CoV-2, or a variant thereof, exhibit neutralizing activity against SARS-CoV-1, SARS-CoV-2, or a variant thereof, and have cross-reactivity, and thus can be used for the prevention or treatment of coronavirus infection. In addition, the antibodies and fragments having immunological activities thereof can be used to rapidly detect various types of coronaviruses, and thus can be used for the immunodiagnosis of human coronaviruses, particularly SARS-CoV-2 with high infectivity, and variants thereof.
Absstract of: WO2025128200A1
Disclosed is a method of treating lung injury in a patient comprising providing a therapeutically effective amount of a pharmaceutical agent that enhances peroxisome biogenesis to a patient. The method includes increasing the number of peroxisomes in alveolar macrophages, decreasing peroxisome degradation, and improving peroxisome function in alveolar macrophages. Increasing the number and function of peroxisomes in alveolar macrophages promotes healing of lung injury and regeneration of alveolar epithelial. The lung injury may be due to infection, including viral infection, such as SARS-CoV-2 infection or influenza infection. The lung injury may also be due to exposure to caustic substances, tobacco smoke, asbestos, or fine particulate matter.
Absstract of: AU2023378779A1
The present disclosure relates to a fusion protein comprising an ectodomain of a viral fusion protein linked to one or more heptad repeat(s) (HR(s)) from a SARS-COV-2 spike (S) protein or a respiratory syncytial virus (RSV) F protein, and the uses thereof. The viral fusion proteins are suitable for use as vaccines.
Absstract of: WO2025125852A1
An oral vaccine for COVID-19 is disclosed. The oral vaccine for COVID-19 includes a delivery platform including Arthrospira platensis with a plurality of host genomes and a plurality of COVID-19 antigen delivery vectors coupled to the plurality of host genomes. Each respective host genome of the plurality of host genomes includes a nucleotide sequence identical to nucleotide sequence of SEQ ID NO. 1. Each COVID-19 antigen delivery vector of the plurality of COVID- 19 antigen delivery vectors has a nucleotide sequence identical to nucleotide sequence of SEQ ID NO. 2. Each respective COVID-19 antigen delivery vector of the plurality of COVID-19 antigen delivery vectors includes at least one antigen of COVID-19 with a weight ratio of the delivery platform to the at least one antigen of COVID-19in a range of 1: 10-3 to 1: 2.5 × 10-3 (delivery platform: at least one antigen of COVID-19).
Absstract of: US2025195464A1
Provided herein are Alotaketal compounds and derivatives thereof that have antiviral activity. In particular, the invention relates to a subset of compounds represented by Formulas (1), (2) and (3), for use as antiviral agents in the treatment or prevention of coronavirus infection. Methods for using the compounds in the treatment or prophylaxis of a coronavirus infection are provided. In particular, the coronavirus infection may selected from one or more of the following: Severe Acute Respiratory Syndrome (SARS) coronavirus-1 (SARS-C0V-1) infection; SARS coronavirus-2 (SARS-C0V-2) infection; and Middle East Respiratory Syndrome (MERS) coronavirus (MERS-CoV) infection. More specifically, the coronavirus infection may be a human coronavirus 229E (HC0V-229E) infection.
Absstract of: EP4570816A1
The present invention relates to a specific inhibitor of IL-6 trans-signaling, the protein sgp130Fc, for use in the treatment or prevention of a disease caused by coronavirus infection in a subject, preferably caused by SARS-CoV-2.
Absstract of: KR20230064339A
The present invention relates to a primer set for ring-mediated isothermal amplification to detect the 2019 novel coronavirus, a composition for detecting the 2019 novel coronavirus containing the same, a kit for detecting the 2019 novel coronavirus containing the same, and a method for detecting the 2019 novel coronavirus using the same. The primer set for ring-mediated isothermal amplification for detecting the 2019 novel coronavirus according to the present invention detects the coronavirus specifically and with high sensitivity (10-3), and can be usefully used for the detection of the coronavirus economically and easily.
Absstract of: WO2025122814A1
The present disclosure relates to methods of diseases and/or conditions associated with Covid-19 infection, including long COVID, comprising administration of a COX-2 inhibitor, an antiviral compound, and one or more additional active ingredients, such as a combination of nirmatrelvir and ritonavir, molnupiravir, BCG vaccine, or ivermectin.
Absstract of: US2025188193A1
This disclosure is based, at least in part, on an unexpected discovery that the novel nanobodies and variants thereof are able to specifically bind afucosylated or sialylated IgG Fc glycoforms. Glycosylation of the IgG Fc domain is a major determinant of the strength and specificity of antibody effector functions, modulating the binding interactions of the Fc with the diverse family of Fey receptors. These Fc glycan modifications, such as removal of the core fucose residue, are newfound clinical markers for predicting severity of diseases, such as diseases caused by dengue virus (DENV) or SARS-CoV-2. However, it remains challenging to accurately distinguish specific IgG glycoforms without costly and time-intensive methods. The novel glycol-specific nanobodies and variants thereof, as disclosed herein, can be used as rapid clinical diagnostics or prognostics to risk stratify patients with viral and inflammatory diseases, as well as therapeutics for patient treatment.
Absstract of: US2025188127A1
The invention relates to a biologically produced nucleic acid sequence comprising two or three primary nucleic acid sequence parts of SARS-COV-2 and not more than three secondary nucleic acid sequence parts, wherein a secondary nucleic acid sequence part encodes an amino acid sequence having the function of a SARS-COV-2 amino acid sequence encoded by ORF3a, ORF6, ORF7a or ORF8. The invention further relates to a host cell or a kit for producing the nucleic acid of the invention, a vector encoding the nucleic acid of the invention and products that can be obtained by the expression of the nucleic acid of the invention such as virus envelopes. The invention further relates a pharmaceutical composition comprising the nucleic acid of the invention or products derived thereof, preferably for use in the prevention of SARS-COV-2.
Absstract of: US2025186609A1
The present disclosure provides methods and compositions for modulating the activity of self-associated molecular pattern recognition receptors such as for example, Siglec (sialic-acid-binding immunoglobulin-type lectins) and complement factor H (CFH). Modulating the activity of infectious organisms such as viral influenza A, B, C, SARS-CoV1, 2, and cancer/tumor cells such as lung, breast and skin cancers. The compositions comprise a particle, comprising a molecule represented by the following structural formula:P-L-G,wherein P is a biocompatible polymer scaffold comprising at least one biocompatible polymer defined herein, G is a polysialic acid (PSA) comprising from 5 to 200 repeat units of sialic acid; and L is a covalent linker, or a pharmaceutically acceptable salt thereof.
Absstract of: US2025186575A1
Disclosed herein are nucleic acid constructs for producing a virus-like particle (VLP) capable of raising an immune response against severe acute respiratory syndrome coronavirus (SARS-CoV), and uses thereof, wherein the constructs comprise nucleic acid sequences encoding an immunogen and a polyprotein, wherein the polyprotein comprises two or more viral structural proteins, wherein at least two of the two or more viral structural proteins are separated by a signal peptidase sequence such that, when the polyprotein is expressed in a host cell, the signal peptidase sequence undergoes host cell peptidase-dependent cleavage to liberate the two or more viral structural proteins, thereby allowing the liberated structural proteins to self-assemble into a VLP carrying the immunogen.
Absstract of: US2025188468A1
Provided are a Forsythia suspensa and Radix astragali compound traditional Chinese medicine decoction-derived micro ribonucleic acid and a preparation method therefor. The micro ribonucleic acid is selected from miRNAs with nucleotide sequences as shown in SEQ ID NOs. 1-15. Further provided are a miRNA QQ_159 with the nucleotide sequence as shown in SEQ ID NO. 14, comprising an artificially synthesized QQ_159, a plant QQ_159, a precursor form of the QQ_159, or a mature form of the QQ_159, use of the miRNA QQ_159 in the preparation of a drug for treating viral pneumonia caused by viral influenza and SARS-COV-2 virus, and a pharmaceutical composition comprising the miRNA QQ_159 and a pharmaceutically acceptable carrier.
Absstract of: US2025188469A1
The present specification provides an antisense oligomer, or a pharmaceutically acceptable salt thereof, or a hydrate of the antisense oligomer or the salt having a length of 15 to 30 bases, comprising a base sequence complementary to a base sequence in a target region, wherein the target region comprises a sequence of at least 10 consecutive bases in at least one region selected from the group consisting of a 5′ UTR region, a nsp1 region, a nsp10 region, an RNA-dependent RNA polymerase region, an ORF10 region, and a 3′ UTR region in the genome RNA of SARS-CoV-2, or a complementary sequence thereof, wherein the antisense oligomer, or the pharmaceutically acceptable salt thereof, or the hydrate of the antisense oligomer or the salt has an antiviral effect on a virus selected from the group consisting of SARS-CoV-2, SARS-CoV-1, and MERS-CoV.
Absstract of: US2025186576A1
The present invention relates to a protein subunit vaccine comprising at least one antigen characterized in that it comprises at least one monomer from at least one variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wherein the at least one monomer is selected from the group consisting of the SI subunit of the Spike protein or the receptor-binding domain (RBD) of the Spike protein. In an aspect of the present invention, the protein subunit vaccine comprises at least one antigen characterized in that it comprises two monomers from at least one variant of SARS-CoV-2, wherein each of the monomers are selected from the group consisting of the S1 subunit or RBD protein, and wherein the monomers are chemically bound to each other, optionally through a linker, forming fusion dimers or non-fusion dimers. The protein subunit vaccine may further comprise at least an adjuvant and at least an immunostimulant.
Nº publicación: US2025186578A1 12/06/2025
Applicant:
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI [US]
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Absstract of: US2025186578A1
Described herein are recombinant Newcastle disease viruses (“NDVs”) comprising a packaged genome, wherein the packaged genome comprises a transgene comprising a nucleotide sequence encoding a protein comprising a SARS-CoV-2 spike protein or portion thereof. Also described herein are recombinant NDVs comprising a packaged genome, wherein the packaged genome comprises a transgene encoding a chimeric F protein, wherein the chimeric F protein comprises a SARS-CoV-2 spike protein ectodomain and NDV F protein transmembrane and cytoplasmic domains. Further, described herein are immunogenic compositions comprising a recombinant NDV(s). The recombinant NDVs and immunogenic compositions are useful for the immunizing against SARS-CoV-2 as well as the prevention of COVID-19.
BOPI
Electronic site
